Recent news on Sirolimus

Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to ...  -  May 22, 2007
PharmaLive.com (press release),The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many

Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial ...  -  May 23, 2007
Medical News Today (press release),Going forward, the company's clinical program will be heavily focused on the study of sirolimus on its platform, as well as on investigating the vast

Establishing Sirolimus Conversion Levels for Kidney Transplant ...  -  May 16, 2007
DG NewsOne such alternative is sirolimus, a type of proliferation signal inhibitor. However, sirolimus has its own unwanted side effect over the long term,

Market Report -- In Play (JNJ)  -  May 22, 2007
MSN MoneyJohnson & Johnson: Cypher Sirolimus-Eluting Coronary Stent had similar results to bypass surgery and better outcomes than bare metal stents Co announces a

Cordis Corporation Announces Activities At EuroPCR 2007  -  May 21, 2007
WebWire (press release),...from the ARTS II Study, which compares the CYPHER® Sirolimus-eluting Coronary Stent versus bypass surgery in patients with multivessel coronary disease.

ISHLT: In Cardiac Transplant, Switching Immunosuppessants Helps ...  -  Apr 26, 2007
MedPage Today,Explain to patients that these studies suggest that switching to sirolimus from calcineurin inhibitors about six months after surgery may preserve kidney

Cordis Corporation Announces Activities at EuroPCR 2007  -  May 18, 2007
netPR.pl (komunikaty prasowe),...which compares the CYPHER(R) Sirolimus-eluting Coronary Stent versus bypass surgery in patients with multivessel coronary disease.

Cordis Corporation Announces Activities at EuroPCR 2007  -  May 18, 2007
Earthtimes.org...from the ARTS II Study, which compares the CYPHER(R)Sirolimus-eluting Coronary Stent versus bypass surgery in patients withmultivessel coronary disease.

Early Results Of The CellCept Spare The Nephron Study Examine ...  -  May 10, 2007
Medical News Today (press release),Dr. Weir reported that first-year results in kidney transplant recipients demonstrated that patients on CellCept and sirolimus maintenance therapy showed

Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent ...  -  May 8, 2007
PipelineReview.com (press release),We expect that the continued development of sirolimus on this platform will demonstrate promising outcomes, because sirolimus has been shown to be a

Registries Confirm Worse Outcome When Drug-Eluting Stents Are Used ...  -  May 9, 2007
MedPage Today,Standard or on-label use for sirolimus-eluting (Cypher) stents was defined as disease because of discrete de novo lesions of 30 mm or less in native

Johnson & Johnson's heart stent fails trial, derailing US plans  -  May 8, 2007
International Herald Tribune,Officers of Johnson & Johnson said it would focus on using sirolimus, the more potent drug the Cypher delivers, in the CoStar's unique stent design.

Changing Heart Transplant Drugs Could Boost Kidney Function  -  Apr 26, 2007
Washington Post,In these studies, the Mayo team examined the use of the immunosuppressive drug sirolimus. Their research received funding from Wyeth Pharmaceuticals,

Heart Transplant Patients Benefit from New Approach to ...  -  Apr 26, 2007
DG NewsKushwaha and a team of Mayo Clinic researchers collaborated to study alternative options for immunosuppression, using sirolimus, an anti-proliferative

Stocks rise as Dow passes 13300 for 1st time  -  May 7, 2007
Minneapolis Star Tribune (subscription),J&J plans to continue developing the stent using the drug sirolimus as a coating, the same coating used on its Cypher stent. Sirolimus is a drug that

Johnson & Johnson CoStar stent fails in study  -  May 8, 2007
newratings.comJohnson & Johnson mentioned that it would now try to develop CoStar II with the drug sirolimus, which is used in its already being marketed drug-coated

Off-Label Drug-Eluting Stent Use Linked With Increased Repeat...  -  May 11, 2007
Medscape (subscription)For these standard indications, the use of sirolimus- or paclitaxel-eluting stents is associated with excellent outcomes and low rates of target lesion

The Enigma of Drug-Eluting Stents Hope, Hype, Humility, and ...  -  May 8, 2007
Journal of American Medical Association (subscription),Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large

Byrnes honored by Thoracic Society  -  May 18, 2007
Checkbiotech.org (press release),LAM and identified the molecular target for the Multicenter International LAM Efficacy of Sirolimus trial, which began enrolling patients in December.

Developments In Stent Technology  -  May 17, 2007
Express Healthcare Management,The first drug used was sirolimus. Subsequently, everolimus, tacrolimus, zotanolimus and paclitaxel have been used on stents in clinical practice.

Key findings on new-generation stent  -  May 13, 2007
News-Medical.net,The Endeavor stent is coated with zotarolimus, a medication that, like the Cypher's sirolimus coating, reduces renarrowing of the artery by preventing the

ENDEAVOR III Trial Reports Key Findings on New-generation Stent  -  May 13, 2007
MedIndia,The Endeavor stent is coated with zotarolimus, a medication that, like the Cypher’s sirolimus coating, reduces renarrowing of the artery by preventing the

SCAI: Diabetics' Stent Outcome Improves with Extended Clopidogrel  -  May 11, 2007
MedPage Today,Of those patients, 221 received bare metal stents and 450 received drug-eluting stents -- either the sirolimus-eluting Cypher stent or the

Stent fails test, won't go forward  -  May 8, 2007
Boston Globe,J&J plans to continue developing the stent using the drug sirolimus, the same coating used on its Cypher stent. The Taxus and Cypher stents are battling for

Changing Heart Transplant Drugs Could Boost Kidney Function  -  26 Apr 2007
Forbes,In these studies, the Mayo team examined the use of the immunosuppressive drug sirolimus. Their research received funding from Wyeth Pharmaceuticals,

CYPHER® Sirolimus-Eluting Coronary Stent Demonstrates Sustained ...  -  Apr 2, 2007
Medical News Today (press release),The SIRIUS (Sirolimus-coated BX VELOCITY® Balloon-Expandable Stent in Treatment of Patients with De Novo Coronary Artery Lesions) Trial, sponsored by Cordis

Two-Year Patient Registry Results Support Safety And Efficacy Of ...  -  Apr 2, 2007
Medical News Today (press release),A large patient registry of "real world" uses for the CYPHER® Sirolimus-eluting Coronary Stent reported favorable safety and efficacy outcomes at two-year

CYPHER® Sirolimus-Eluting Coronary Stent Had Similar Results To ...  -  Apr 2, 2007
Medical News Today (press release),The CYPHER® SELECT™ Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets

Cypher(R) Sirolimus-Eluting Coronary Stent had Similar Results to ...  -  Mar 28, 2007
PR Newswire UK (press release),Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use,

APS: Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates .....  -  Mar 28, 2007
ANP Pers Support,...was preserved from the initial nine-month follow-up out to five years. In addition, no. of myocardial infarction (heart attack), death or stent thrombosis

MacuSight(TM) to Present at IBC's 4th International Conference on ...  -  Apr 10, 2007
PR Newswire (press release),Dr. Weber's presentation will take place at 2:45 pm EDT on Tuesday, April 17th and will focus on the role of sirolimus (rapamycin) as a potential

MacuSight(TM) to Present at IBC's 4th International Conference on ...  -  Apr 10, 2007
PR-Inside.com (Pressemitteilung),...and will focus on the role of sirolimus (rapamycin) as a potential therapeutic for the treatment of a variety of serious ocular diseases and conditions,

Market Report -- In Play (JNJ)  -  Mar 27, 2007
MSN MoneyJohnson & Johnson announces Cypher sirolimus-eluting coronary stent demonstrates sustained benefits vs bare-metal stents in trial Co announces clinical

Studies from Germany, the United States and the Netherlands update ...  -  Apr 5, 2007
Therapeutics Daily (subscription) (press release),Study 1: Investigators publish new data in the report "Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone

Clopidogrel and Long-term Outcomes After Drug-Eluting Stent ...  -  Apr 24, 2007
Journal of American Medical Association (subscription),A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780. FREE FULL TEXT

Studies Highlight 'real World' Use, Safety Of Drug-eluting Stents  -  Apr 3, 2007
Medical News Today (press release),Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis (RE-CLOSE) Trial (Presentation Number: 2414-7) Patients who do not

Micell Technologies presents data on novel drug-eluting stents  -  Apr 20, 2007
News-Medical.net,...technology to create drug-eluting stents containing crystalline drugs, such as sirolimus, and multiple drug combinations such as paclitaxel and heparin.

DES vs CABG in higher-risk patients: No early morbidity advantage ...  -  Apr 19, 2007
TheHeart.Org,Also in the DES news this week, Johnson & Johnson announced during a conference call that sales of its Cypher sirolimus-eluting stent have dropped by 35% in

Micell Technologies Presents Data on Novel Drug-Eluting Stents  -  Apr 18, 2007
PR Newswire (press release),2006 R&D 100 Award winning e-RESS technology to create drug-eluting stents containing crystalline drugs, such as sirolimus, and multiple drug

Case 12-2007 — A 56-Year-Old Woman with Renal Failure after Heart ...  -  Apr 18, 2007
New England Journal of Medicine (subscription),There are two agents in this class, sirolimus and everolimus. Both are known to cause bone marrow suppression, hyperlipidemia, and delayed wound healing,

Boston Scientific loses patent case against J&J  -  Apr 6, 2007
Bizjournals.com,Johnson & Johnson's Cypher uses sirolimus, a medicine that prevents buildup of excessive scar tissue around the devices. Drug-coated stents such as Cypher

Two-year results from ENDEAVOR III point to safety, efficacy  -  Apr 4, 2007
TheHeart.Org,III trial suggests that the Endeavor zotarolimus-eluting stent may be equivalent to the sirolimus-eluting Cypher stent, in terms of clinical end points.

New Cancer Practice Guidelines Recommend NOXAFIL(R) (Posaconazole ...  -  Apr 2, 2007
Drug Newswire (press release),...tacrolimus, or sirolimus and frequent monitoring of drug levels of these medications is necessary when taking them in combination with NOXAFIL.

Giving COURAGE Its Due  -  Apr 6, 2007
MedPage Today,David E. Kandzari, MD, chief medical officer at Cordis Cardiology Division of Johnson & Johnson, which makes Cypher, a sirolimus-eluting coronary stent,

Study: Cypher stent beats bare-metal  -  Mar 27, 2007
United Press InternationalData from the SIRIUS study showed patients implanted with the Cypher sirolimus-eluting coronary stent had lower rates of cardiac death, heart attack and

SIROCCO Trial Shows Minimal Long-Term Restenosis Rates With Cordis ...  -  Feb 23, 2007
Earthtimes.orgThe SIROCCO study included 93 patients in two treatment arms: 47 patientsreceived the sirolimus-eluting SMART (R) stent and 46 patients receiveda bare

UPDATE 1-US FDA says Roche cancels heart transplant study  -  Feb 22, 2007
Reuters..."The safety and efficacy of CellCept in combination with sirolimus following withdrawal of initial calcineurin inhibitor therapy has not been established,"

A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with ...  -  Feb 12, 2007
New England Journal of Medicine (subscription),Methods We performed a pooled analysis of 1748 patients in four randomized trials evaluating the safety of sirolimus-eluting stents as compared with

Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary ...  -  Feb 12, 2007
New England Journal of Medicine (subscription),Results The 4-year rates of stent thrombosis were 1.2% in the sirolimus-stent group versus 0.6% in the bare-metal-stent group (P=0.20) and 1.3% in the

FDA Approves New Dosing Recommendations for Rapamune(R) (Sirolimus ...  -  Feb 2, 2007
DG NewsA total of 224 patients received a transplant and at least one dose of Rapamune (sirolimus) and cyclosporine and was comprised of 77.2% Black patients,

FDA says Roche cancels heart transplant study  -  Feb 22, 2007
Reuters.uk,...were switched from a regimen of calcineurin inhibitor and the company's immunosupressant drug CellCept to the immunosupressant drug sirolimus and CellCept.

Roche weathers a hard week  -  Feb 24, 2007
Monsters and Critics.com,Spare The Nephron, was terminated because of a higher incidence of organ rejection in heart-transplant patients switched off of CellCept to sirolimus.

Multiple Articles in the New England Journal of Medicine Confirm ...  -  Feb 12, 2007
PR Newswire (press release),CYPHER(R) SELECT(TM) Plus, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets

Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents  -  Feb 12, 2007
New England Journal of Medicine (subscription),Results The cumulative incidence of stent thrombosis according to the original protocol definitions was 1.2% in the sirolimus-stent group versus 0.6% in the

Cordis Corporation's manufacturing facility recognised with Shingo ...  -  Feb 9, 2007
Prdomain Business Register (press release),The Juarez facility plays an instrumental role in the manufacturing of Cordis' innovative medical devices, such as the CYPHER® Sirolimus-eluting Coronary

Drug-Eluting Stents Best After Artery Re-Closure  -  Jan 29, 2007
Forbes,In another study in the same journal issue, Italian researchers looked at drug-eluting stents to see which medication, sirolimus or paclitaxel, worked best.

Rapamune OK'd for high-risk transplants  -  Feb 2, 2007
United Press InternationalThe drug, sirolimus, also known as rapamycin, received an indication to treat high-risk kidney-transplant patients -- individuals who are African-American,

Stents: Benefits vs. risks  -  Feb 23, 2007
Albany Democrat Herald,The two stents most widely used in the United States — one by J & J and the other by Boston Scientific — are coated, respectively with sirolimus or

Bern-Rotterdam analysis published: DES stent thrombosis risk ...  -  Feb 23, 2007
TheHeart.Org,...first with the sirolimus-eluting stent (SES; in 3823 patients), followed by the paclitaxel-eluting stent (PES; in 4323 patients). Over the study period,

FDA Approves New Dosing Recommendations for Rapamune in High ...  -  Feb 2, 2007
PharmaLive.com (press release),A total of 224 patients received a transplant and at least one dose of RAPAMUNE (sirolimus) and cyclosporine and was comprised of 77.2 percent Black

Drug-eluting Coronary Stents-A Wealth of Data and Little Agreement  -  Feb 12, 2007
MedPage Today,Three of the five papers analyzed data from pivotal trials of Cypher (sirolimus-eluting) stent and/or the Taxus (paclitaxel-eluting) stent.

Boston Scientific Welcomes New England Journal of Medicine ...  -  Feb 15, 2007
Drug Newswire (press release),Similar examination comparing 878 patients who received Cordis' Cypher(R) sirolimus- eluting coronary stent (Cypher Stent) to 870 patients who received a

Sección internacional  -  Feb 12, 2007
Bolsamania.com,...(PRN) - Multiple Articles in the New England Journal of Medicine Confirm On-Label, Long-Term Safety and Efficacy of the CYPHER(R) Sirolimus-Eluting Coronary

Lean Manufacturers Recognized for Excellence  -  Feb 9, 2007
PR Newswire (press release),...leader in developing and manufacturing interventional vascular technology, including the groundbreaking CYPHER(R) Sirolimus-eluting Coronary Stent.

12 world-class manufacturing plants win '07 Shingo Prize  -  Feb 9, 2007
Reliable Plant Magazine,...is a worldwide leader in developing and manufacturing interventional vascular technology, including the groundbreaking CYPHER Sirolimus-eluting Coronary

Lean Manufacturers Recognized for Excellence  -  Feb 8, 2007
Yahoo! News (press release)...leader in developing and manufacturing interventional vascular technology, including the groundbreaking CYPHER® Sirolimus-eluting Coronary Stent.

Cordis plant in Mexico named 2007 Shingo Prize winner  -  Feb 8, 2007
Reliable Plant Magazine,The Juarez facility plays an instrumental role in the manufacturing of Cordis' innovative medical devices, such as the CYPHER Sirolimus-eluting Coronary

Drug-Eluting Stents Best After Artery Re-Closure  -  Jan 29, 2007
Washington Post,The stents used in the study were coated with either the drug sirolimus or another drug, paclitaxel. The studies included 1230 patients whose bare metal

Juiced-Up Medicine  -  18 Jan 2007
ABC7Chicago.com,But now, researchers at the University of Chicago Hospitals are purposely pairing grapefruit juice with a medication known as sirolimus, or Rapamycin.

Innovators take aim at clogged hearts  -  Jan 11, 2007
OCRegister,In 2003, the FDA approved the first stent that released a drug, Sirolimus, to combat the problem of renewed plaque deposits. Called a drug-eluting stent,

Does Clopidogrel Each Day Keep Stent Thrombosis Away?  -  Jan 9, 2007
Journal of American Medical Association (subscription),Following approval of the sirolimus-eluting stent, sweeping adoption of this promising new technology into clinical practice occurred as it appeared that

Drug-Eluting Stents: Innovative Devices Fill Pipeline  -  Jan 15, 2007
MedPage Today,He was a consultant to the FDA Circulatory System Devices Advisory Panel that met here in December for two days on the safety of Cypher (sirolimus-eluting)

Study in European Heart Journal Favors Taxus(R) Stent Over Cypher ...  -  Jan 15, 2007
DG News...rate and equal or lower instances of death or heart attack than the Cypher(R) sirolimus-eluting stent (SES) and bare- metal stents (BMS).

Drug-eluting Stents Impede Coronary Collateral Function  -  Dec 27, 2006
MedPage Today,The authors said that evidence from animal studies suggests that sirolimus (Rapamycin) has anti-angiogenic properties, which would explain the apparent

Does Clopidogrel Each Day Keep Stent Thrombosis Away?  -  Jan 9, 2007
Journal of American Medical Association (subscription),...relative safety and efficacy of drug-eluting stents, the US Food and Drug Administration approved both Cypher, the sirolimus-eluting stent, in 2002, .

Primary PCI for Myocardial Infarction with ST-Segment Elevation  -  Jan 3, 2007
New England Journal of Medicine (subscription),Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-2117.

Axis-Shield 2006 Pre-Close Trading Update  -  Jan 5, 2007
WebWire (press release),We also expect to show good 2006 revenue increases from our AxSYM® assay for testosterone and our kit for sirolimus (which monitors blood levels of this

Research and Markets: Examine the Latest Mergers & Acquisitions ...  -  Jan 4, 2007
American Digital Networks (press release),Cordis' main product line is its Cypher Sirolimus-Eluting Stent, the world's best-selling drug-eluting stent (DES). J&J's planned acquisition of Conor

Research and Markets: Cordis Medical Device Company May Be ...  -  Jan 4, 2007
Business Wire (press release),Beerse, Belgium; and Latina, Italy, including sites involved in the production of the Cypher sirolimus-eluting stent and Precise Nitinol biliary stent.

Another New Study Finds Risks with Drug-Coated Stents  -  Jan 3, 2007
Newsinferno.com,...they concluded: “Collateral function long after coronary stenting is impaired with DES (sirolimus and paclitaxel) when compared with BMS.

Making Sense of Drug-Coated Stents  -  Jan 1, 2007
Newsinferno.com,...procedures were being delayed specifically to await the FDA’s approval of the Cypher, Cordis’ revolutionary Sirolimus-Eluting Coronary Stent.

ACC/AHA/ESC 2006 Guidelines - Preventing thromboembolism in ...  -  Dec 23, 2006
Xagena.it,Clopidogrel should be given for a minimum of 1 mo after implantation of a bare metal stent, at least 3 mo for a Sirolimus-eluting stent, at least 6 mo for a

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional